

**Remarks**

In order to expedite prosecution of the present application, Applicants submit herein amendments to the pending claims.

Claim 1 has been amended by limiting the value R4 to  $\text{NHSO}_2\text{CH}_3$  and the value of R5 to hydrogen. Basis for this amendment may be found in the original claims, as well as the specification at pages 29 (line 32) and 30 (line 1). In view of the proposed amendment to Claim 1, Claims 13-17 have been cancelled as they are no longer properly dependent upon Claim 1. Claims 26 and 28 have been amended to correct the misspelling of the word "administering." New Claim 34 is drawn to a markush group consisting of the compounds claimed in previously presented Claims 29-33, which have now been cancelled.

As the present amendments merely narrow the scope of the claimed invention, or reduce the number of claims, Applicants submit that said amendments encompass no added matter. Applicants respectfully request entry of the present amendments and passage of the application for examination.

Respectfully submitted,

/Alexander Wilson/

Alexander Wilson  
Attorney for Applicants  
Registration No. 45,782  
Phone: 317-277-0190

Eli Lilly and Company  
Patent Division  
P.O. Box 6288  
Indianapolis, Indiana 46206-6288

September 5, 2007